Beyond Air Inc - SIC # 3841 - SURGICAL AND MEDICAL INSTRUMENTS AND APPARATUS

Ticker Exchange SIC # Website Latest Ticker
XAIR Nasdaq 3841 https://www.beyondair.net/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Beyond Air Inc

Beyond Air® Schedules Fiscal Year End 2023 Financial Results Conference Call and Webcast - May 16th, 2023 8:05 pm
Beyond Cancer™ Presents Positive Preclinical Data for Ultra-High Concentration Nitric Oxide (UNO) Therapy in Solid Tumors During the American Association for Cancer Research (AACR) 2023 Annual Meeting - Apr 19th, 2023 1:00 pm
Beyond Air® Appoints Jeff Myers, M.D. Ph.D. as Chief Medical Officer - Mar 23rd, 2023 8:05 pm
Beyond Cancer™ to Present Two Posters for Ultra-High Concentration Nitric Oxide (UNO) Therapy at the 2023 AACR Annual Meeting - Mar 14th, 2023 8:35 pm
Beyond Air® Announces Participation at Two Upcoming Investor Conferences in March 2023 - Feb 22nd, 2023 12:00 pm
Beyond Air® Reports Financial Results for the Third Quarter of Fiscal Year 2023 - Feb 9th, 2023 9:05 pm
Beyond Cancer® Appoints Gavin Choy, PharmD as Chief Operating Officer - Jan 30th, 2023 12:00 pm
Beyond Cancer® Announces Sponsored Research Agreement with Stanford and Appointment of Frederick M. Dirbas, MD and Mark D. Pegram, MD to Scientific Advisory Board - Jan 24th, 2023 9:05 pm
Beyond Air® Schedules Third Fiscal Quarter 2023 Financial Results Conference Call and Webcast - Jan 17th, 2023 9:05 pm
Beyond Cancer® Publishes Pre-Clinical Data in Cancer Cell International Demonstrating Its Tumor Ablation Method Utilizing Ultra-High Concentration Nitric Oxide (UNO) Induced a Systemic Response that Prevents Metastases - Dec 13th, 2022 2:25 pm
Beyond Air® To Participate in Piper’s 34th Annual Healthcare Conference - Nov 17th, 2022 9:05 pm
Beyond Cancer™ Presents Promising New In Vivo Data Showing Ultra-High Concentration Nitric Oxide Therapy (UNO) in Combination with Anti-PD-1 During the Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting - Nov 10th, 2022 2:00 pm
Beyond Air® Reports Financial Results for the Second Quarter of Fiscal Year 2023 - Nov 8th, 2022 9:05 pm
Beyond Air® Announces Positive Data for Inhaled Nitric Oxide (NO) to Treat COVID-19 with LungFit® PRO in a Poster Presentation at IDWeek 2022 - Oct 24th, 2022 11:30 am
Beyond Air® Schedules Second Fiscal Quarter 2023 Financial Results Conference Call and Webcast - Oct 20th, 2022 8:05 pm
Beyond Air® Announces Positive Data from At-Home Pilot Study in Patients with Refractory NTM Lung Infection Treated with (NO) using the LungFit® GO at the CHEST Annual Meeting 2022 - Oct 17th, 2022 8:05 pm
Beyond Cancer™ to Present Pre-Clinical Data for Ultra-High Concentration Nitric Oxide Therapy at the 2022 SITC Annual Meeting - Oct 5th, 2022 12:00 pm
Beyond Air® Announces that Annals of the American Thoracic Society Published a Review of the Third Pilot Study of High Dose Nitric Oxide for Bronchiolitis - Oct 3rd, 2022 11:30 am
Beyond Air® To Participate in Three Upcoming Investor Conferences - Sep 16th, 2022 8:05 pm
Beyond Air® Affiliate Beyond Cancer™ Doses Initial Patient in First-in-Human Phase 1 Study of Ultra-High Concentration Nitric Oxide Therapy at Tel Aviv Sourasky Medical Center (Ichilov) - Aug 23rd, 2022 12:00 pm